Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

NEKTAR THERAPEUTICS (NKTR)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/13/2018 06/14/2018 06/15/2018 06/18/2018 06/19/2018 Date
53.47(c) 56.41(c) 57.86(c) 58.41(c) 57.36(c) Last
4 442 618 5 199 262 7 403 071 3 799 444 3 672 143 Volume
-0.17% +5.50% +2.57% +0.95% -1.80% Change
More quotes
Financials (USD)
Sales 2018 1 179 M
EBIT 2018 669 M
Net income 2018 620 M
Debt 2018 -
Yield 2018 -
Sales 2019 277 M
EBIT 2019 -231 M
Net income 2019 -260 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 15,65
P/E ratio 2019
Capi. / Sales2018 8,41x
Capi. / Sales2019 35,9x
Capitalization 9 917 M
More Financials
Company
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms.It operates through the United States and Europe geogrpahical segments.The company was founded in 1990 and is... 
Sector
Biotechnology & Medical Research
Calendar
06/26 | 08:00pmShareholder meeting
More about the company
Surperformance© ratings of Nektar Therapeutics
Trading Rating : Investor Rating :
More Ratings
Latest news on NEKTAR THERAPEUTICS
06/14NEKTAR THERAPEUTICS : New Data for NKTR-181, a First-in-Class Investigational Op..
PR
06/08FRIDAY 6/8 INSIDER BUYING REPORT : Yumc, nktr
AQ
06/07SYNDAX PHARMACEUTICALS : and Nektar Therapeutics Announce Immuno-Oncology Clinic..
AQ
06/07NEKTAR THERAPEUTICS : Entry into a Material Definitive Agreement (form 8-K)
AQ
06/06NEKTAR THERAPEUTICS : Bristol-Myers Squibb - Preliminary Data for NKTR-214 in Co..
AQ
06/05NEKTAR THERAPEUTICS : to Webcast Presentation at the Jefferies 2018 Healthcare C..
PR
06/05NEKTAR THERAPEUTICS : Today's Research Reports on Trending Tickers: Nektar Thera..
AC
06/05NEKTAR THERAPEUTICS : - Preliminary Data for NKTR-214 in Combination with Opdivo..
AQ
06/04Merck and TJX climb; Nektar Therapeutics slumps
AQ
06/04NEKTAR THERAPEUTICS : Other Events (form 8-K)
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
02:01pAlexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
12:30pCowen's health care team publishes investment takeaways from our conference c.. 
06/14$1.04 Billion in Sales Expected for Nektar Therapeutics $NKTR This Quarter  
06/14$NKTR Jan 2020 60/100 call spreads opening 500X today 
06/14$NKTR New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat..
1
06/13RECAP 6/13 Unusual Puts: $ETSY $CAT $WFT $SMH $ATVI $NKTR $TUR $AMLP $GNC
2
More tweets
Qtime:96
News from SeekingAlpha
06/17ROUNDS REPORT : Solid Biosciences Rallied While FDA Approved The First Generic S.. 
06/16INSTITUTIONAL TOP IDEAS : Cormorant Asset Management 
06/16A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals 
06/13ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed 
06/12NEKTAR THERAPEUTICS : In The Midst Of A Difficulty An Opportunity Arises 
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | 4-Traders
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 96,8 $
Spread / Average Target 66%
EPS Revisions
Managers
NameTitle
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Research & Development Officer, Senior R&D
Sector and Competitors
1st jan.Capitalization (M$)
NEKTAR THERAPEUTICS-3.11%9 917
CELLTRION, INC.--.--%33 912
IQVIA HOLDINGS INC7.13%21 394
LONZA GROUP3.38%20 435
INCYTE CORPORATION-21.91%15 677
ALNYLAM PHARMACEUTICALS, INC.-15.15%10 836